Nadi Tarangini, an indigenously developed pulse diagnostic tool, has become India’s first ayurvedic medical device to receive ...

Drugmaker Wockhardt on Thursday announced Central Drugs Standard Control Organization (CDSCO) approval for use of ... plans to launch Miqnaf in the Indian market in coming few months, Wockhardt ...

Shares of Wockhardt are higher by 5% on January 3 after Indian drug regulator ... in an exchange filing. Central Drugs Standard Control Organization (CDSCO) approved antibiotic Nafithromycin ...

Pune: Nadi Tarangini, the country's first ayurvedic diagnostic tool to receive approval from Central Drugs Standard Control Organization (CDSCO), is e.

Despite the glorious performance of the pharmaceutical sector, India faced a huge setback because of the recent incident when ...

Given that more than 40% of Indian adults are struggling with obesity and diabetes, affordable weight-loss drugs are expected ...

getting regulatory approval from the Central Drugs Standard Control Organization. Wockhardt expects to launch this product in Indian, in about two-three months, as local clearances are to be taken ...

The 52-week low of the stock stood at Rs 402.85 per share. "The Indian drug regulator, Central Drugs Standard Control Organization (CDSCO) has approved Miqnaf (nafithromycin) as a new treatment for ...

Pune-based startup Atreya Innovations has developed an AI-powered pulse diagnostic tool for Ayurveda practitioners, 'Nadi ...

Pharmaceuticals firm Wockhardt Ltd on Thursday (January 2) announced that the Central Drugs Standard Control Organization (CDSCO) has approved Miqnaf (nafithromycin ... South Africa and India. It ...

The uptick in the stock price was seen after Wockhardt informed the exchanges that Indian drug regulator, Central Drugs Standard Control Organization (CDSCO), approved a medicine of the company. CDSCO ...